Table 3. Outcome for patients by treatment after progression on bevacizumab study therapy.
| Group | Total | No. of patients failed | Median survival in months (95% CI) | 6-Month survival % (95% CI) | 12-Month survival % (95% CI) | 24-Month survival % (95% CI) | P -value a |
|---|---|---|---|---|---|---|---|
| OS from initiation of subsequent treatment | |||||||
| No treatment | 41 | 41 | 1.5 (0.7, 2.1) | 4.9 (0.9, 14.5) | 2.4 (0.2, 11) | 0 | |
| Non-BV therapy | 44 | 44 | 4.0 (2.1, 5.4) | 29.5 (17.0, 43.2) | 4.5 (0.8, 13.6) | 0 | |
| BV therapy | 55 | 48 | 5.9 (4.4, 7.6) | 49.2 (35.2, 61.8) | 13.2 (5.5, 24.4) | 3.3 (0.3, 13.1) | 0.0138 |
| PFS from initiation of subsequent treatment | |||||||
| Non-BV therapy | 44 | 44 | 1.6 (1.2, 1.8) | 2.3 (0.2, 10.4) | 2.3 (0.2, 10.4) | 0 | |
| BV therapy | 55 | 50 | 2.8 (1.7, 3.5) | 15.6 (7.3, 26.6) | 5.8 (1.2, 15.9) | 2.9 (0.3, 12.4) | <0.0001 |
Abbreviations: BV=bevacizumab; CI=confidence interval; NE=not-evaluable; OS=overall survival; PFS=progression-free survival.
a
From the Cox model without adjustment for covariates.